Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.

Also called NCT05963568

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05963568
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Benin, Ghana, Nigeria, Tanzania (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05963568. Randomized; single masking; primary purpose prevention. Start 2026-04-01 (actual); primary completion 2029-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II)
Condition
Stroke
Condition
Medication Adherence
Intervention (Drug)
Polycap
Lead sponsor
Northern California Institute of Research and Education (class: other)

Record details

Record id
cardio:ct-nct05963568
Content hash
32ea2c0d3bde52230546d804c436aa39d6f32bf23ef532384559784f101e2100